CEO Executive AssistantClinical trials are among the most complex, highest-stakes, and most closely regulated programs a healthcare organization manages. For the healthcare CEO overseeing a clinical research portfolio, the administrative demands are substantial: research governance committee oversight, FDA regulatory engagement, protocol enrollment tracking, industry sponsor relationship management, and board-level reporting on trials portfolio strategy and commercial potential.
Clinical trials administration coordination at the executive level is not about scientific oversight. It is about ensuring that the CEO has the information, the stakeholder access, and the organizational infrastructure to govern the research program effectively, communicate its value to the board and investors, and maintain the institutional relationships that make the research enterprise viable.
Executive assistants who master this coordination function become essential partners to healthcare CEOs navigating one of the most regulated and consequential programs in their organization’s portfolio. This article explains how that partnership works in practice.
The Governance Complexity of Clinical Trials Administration
Healthcare CEOs who oversee clinical research programs manage a governance structure that is more layered than most other executive functions. The institutional review board governs human subjects protection. The research governance committee oversees scientific integrity and resource allocation. The FDA regulates trial conduct for studies seeking regulatory approval. Industry sponsors have contractual oversight rights. Institutional compliance functions conduct periodic audits.
Each of these governance relationships generates its own meeting cadence, reporting cycle, and documentation requirement. The CEO’s role within this structure is strategic: setting research investment priorities, ensuring that governance processes are functioning properly, managing key external relationships, and reporting to the board on how the clinical trials portfolio serves the organization’s mission and financial objectives.
Harvard Business Review research on healthcare leadership effectiveness identifies the management of complex regulatory relationships as one of the critical competencies distinguishing high-performing healthcare executives. Clinical trials administration coordination is precisely where that competency is tested.
Scheduling IRB and Research Governance Committee Meetings
The institutional review board is the cornerstone of human subjects protection in clinical research. IRB meetings follow a regular cycle, typically monthly for full board reviews and with expedited review procedures for lower-risk protocols. The CEO’s interface with the IRB is primarily at the governance level: ensuring the board is properly resourced, addressing systemic issues identified in IRB operations, and receiving reports on the institution’s human subjects research compliance posture.
The executive assistant manages the CEO’s IRB-related calendar functions. This includes scheduling periodic briefings from the IRB chair or administrator so the CEO receives current status on submission volumes, review turnaround times, and any compliance concerns. When the CEO is scheduled to address the full IRB or participate in research governance committee meetings, the EA coordinates preparation materials well in advance and confirms logistics with committee administrators.
Research governance committee meetings require more direct CEO engagement. These committees review new research proposals, monitor ongoing studies for scientific and operational progress, and make resource allocation recommendations. The EA coordinates the CEO’s preparation for governance committee meetings, working with the research administration team to compile portfolio summaries, flagged issues requiring CEO input, and decision items that require executive authority.
When governance committee meetings surface issues requiring rapid CEO response, such as sponsor audit findings, protocol deviations, or enrollment concerns on high-priority studies, the EA facilitates ad hoc briefings and coordinates the CEO’s engagement with the relevant stakeholders.
Coordinating FDA Regulatory Submission Briefings
FDA regulatory engagement is one of the most consequential and time-sensitive dimensions of clinical trials administration. Pre-IND meetings, Type A and Type B meeting requests, response to information requests, and the broader strategy of the organization’s regulatory pathway for key research programs all require CEO awareness and, at critical junctures, CEO judgment.
The executive assistant coordinates CEO briefings on FDA regulatory matters by working with the regulatory affairs team to structure information delivery around decision points rather than administrative updates. Not every FDA interaction requires CEO time. The EA helps the regulatory affairs leadership identify which regulatory developments rise to the CEO’s attention threshold and structures briefing sessions around those events.
When a critical regulatory meeting with the FDA is being prepared, the EA coordinates the internal rehearsal process: scheduling dry-run sessions with the regulatory team, ensuring that the CEO’s preparation materials are ready in advance, and managing the logistics of FDA meeting attendance if the CEO participates directly in Type B or Type C meetings.
For regulatory submission milestones on priority programs, the EA tracks submission deadlines and builds a forward-looking regulatory calendar that shows the CEO upcoming FDA engagement points across the portfolio. This allows strategic preparation rather than reactive response when submission windows arrive.
Supporting board-level reporting on regulatory strategy is a function the EA coordinates alongside regulatory briefing management, ensuring that board materials accurately reflect the current regulatory status of priority programs without overstating or understating the organization’s regulatory position.
Tracking Protocol Enrollment and Milestone Reporting
Clinical trial enrollment is where the strategic ambitions of a research program meet operational reality. Studies that enroll below projections require intervention: site activation adjustments, protocol amendments, or sponsor renegotiation. Studies that enroll ahead of schedule require resource allocation responses and may trigger early milestone payment opportunities.
The executive assistant creates and maintains an enrollment tracking dashboard that gives the CEO current visibility into enrollment status across the active trials portfolio. This dashboard is not a research operations tool; it is a strategic summary that shows enrollment versus plan, projected milestone achievement dates, and flagged studies requiring executive attention.
Monthly enrollment reporting cycles are coordinated by the EA, who works with the research operations team to collect updated site-level enrollment data and compile it into CEO briefing format. The EA flags studies with significant enrollment gaps well in advance of milestone reporting deadlines so the CEO has time to engage sponsors or make operational decisions before situations become crises.
For externally reported milestones, including those that trigger sponsor payments or meet investor-facing research timeline commitments, the EA ensures that milestone documentation is prepared and submitted on schedule. A missed milestone report to a sponsor can trigger financial penalties or damage sponsor relationships that took years to build.
Managing Industry Sponsor Relationship Meetings
Industry sponsors, whether pharmaceutical companies, device manufacturers, or biotech firms funding investigator-initiated research, are among the healthcare organization’s most important external relationships. Sponsor relationships drive research revenue, influence the organization’s research reputation, and can be a pipeline for future investment and collaboration opportunities.
The executive assistant manages the CEO’s sponsor relationship calendar with the same rigor applied to investor relations in other industries. Regular relationship touchpoints with major sponsors are scheduled proactively, not reactively. Pre-meeting briefing packages include sponsor history, current active studies, enrollment and milestone performance data, and any open issues or opportunities the CEO should address.
When sponsor organizations conduct periodic site audits or program reviews, the EA coordinates the CEO’s participation at the appropriate governance level and ensures that the research administration and compliance teams are prepared for sponsor review activities. The EA manages the scheduling of sponsor audit exit briefings with the CEO so that any findings are understood and response commitments are documented promptly.
New sponsor development meetings require different preparation. The EA coordinates introductory briefings that position the organization’s research capabilities in terms the sponsor finds relevant, drawing on the research portfolio summary and the compliance track record. First impressions in sponsor development are heavily influenced by how organized and prepared the CEO’s office appears, and EA preparation is where that impression is built.
Supporting strategic planning coordination connects clinical trials portfolio decisions to broader organizational strategy. The EA ensures that the CEO’s research investment priorities are aligned with the strategic plan and that sponsor development efforts reflect the organization’s long-term research positioning goals.
Preparing Board Presentations on Clinical Trials Portfolio Status
The board of directors oversees the clinical trials program as part of its governance of the organization’s research mission and as a significant driver of financial performance for research-intensive institutions. Board presentations on clinical trials need to address both mission fulfillment and financial performance in terms that non-scientists on the board can understand and evaluate.
The executive assistant coordinates the preparation of board presentations on clinical trials portfolio status on a defined schedule, typically aligned with the board’s standing meeting calendar. These presentations are developed in collaboration with research administration, finance, regulatory affairs, and the CEO’s strategy team.
A well-structured clinical trials board presentation covers the active portfolio by therapeutic area and sponsor type, enrollment performance versus plan across priority studies, regulatory milestone achievement in the trailing period, research revenue and expense versus budget, and the pipeline of new studies under development with projected activation timelines.
The translational commercialization section of the board presentation is particularly important for healthcare CEOs at research-intensive institutions. Boards want to understand which research programs have commercial potential, what the pathway from research to commercialization looks like, and how the organization is positioned to capture value from its research investment. The EA coordinates input from technology transfer, licensing, and strategy teams to populate this section with current and accurate information.
Board material preparation begins four to six weeks before the board meeting date. The EA’s preparation schedule includes data collection deadlines for each contributing team, a first draft completion date that allows adequate CEO review time, revision and approval milestones, and a final distribution date that meets board governance requirements for advance material review.
Building the Clinical Trials Calendar Infrastructure
The administrative infrastructure underlying all clinical trials coordination functions is the master research calendar the EA builds and maintains. This calendar integrates IRB meeting cycles, FDA regulatory engagement milestones, enrollment reporting deadlines, sponsor relationship touchpoints, board presentation schedules, and compliance audit cycles.
A mature clinical trials calendar infrastructure operates on multiple time horizons simultaneously. The near-term view (30 days) shows immediate deadlines, scheduled meetings, and this week’s CEO preparation requirements. The medium-term view (90 days) shows upcoming milestone reporting dates, sponsor visits, and board preparation start dates. The long-term view (12 months) shows the regulatory submission calendar, annual IRB reporting cycles, and sponsor contract renewal dates.
The EA distributes a weekly clinical trials briefing to the CEO that surfaces the most important near-term items across all coordination functions. This briefing is the CEO’s primary tool for staying current on clinical trials administration without needing to monitor multiple systems or attend operational-level meetings.
Conclusion
Clinical trials administration coordination is one of the most demanding and consequential administrative functions an executive assistant manages for a healthcare CEO. The combination of IRB governance, FDA regulatory engagement, enrollment tracking, sponsor relationship management, and board reporting creates a coordination workload that affects research program performance, institutional compliance, and organizational reputation.
For healthcare CEOs overseeing research-intensive organizations, the executive assistant who manages clinical trials administration coordination with precision and expertise creates measurable operational value. Well-coordinated governance meetings lead to better research oversight. Accurate enrollment tracking enables earlier intervention when programs fall behind. Professional sponsor relationship management protects and expands revenue. Coherent board presentations build the board confidence that supports research investment. Each of these outcomes depends directly on the quality of clinical trials administration coordination, and that quality starts with the CEO’s administrative infrastructure.